OBJECTIVE: Leukocyte traffic from the blood to the joints is crucial in the pathogenesis of arthritis. A bifunctional endothelial cell-surface glycoprotein, AOC3 (amine oxidase, copper-containing 3; also known as vascular adhesion protein 1), has both adhesive and enzymatic properties. We undertook this study to determine the contribution of AOC3 and its oxidase activity to leukocyte trafficking into inflamed joints in vivo. METHODS: We used gene-modified animals, molecular modeling, an AOC3 enzyme inhibitor, oxidase assays, and arthritis models (adjuvant-induced arthritis [AIA] in rats and anti-type II collagen antibody-induced arthritis in mice) to dissect the importance of AOC3 in vivo. RESULTS: The AOC3 inhibitor fitted well with a covalent binding mode into the active site of the AOC3 crystal structure. It selectively blocked the oxidase activity of AOC3 in enzyme assays. Intraperitoneal and oral administration of the AOC3 inhibitor significantly ameliorated rat AIA. In anti-type II collagen antibody-induced arthritis in mice, the AOC3 inhibitor also improved the outcome of the joint inflammation. The acute semicarbazide-sensitive amine oxidase blockade by the inhibitor had even more pronounced effects than genetic deletion of AOC3. Enzymatic analyses showed that the inhibitor also blocked 2 other structurally very closely related AOCs, but not any of more than 100 other enzymes tested. CONCLUSION: These are the first data to demonstrate that the enzymatic activity of the atypical endothelial adhesion molecule AOC3, and possibly that of other closely related ecto-oxidases, is crucial for leukocyte exit from the vessels in inflamed joints in vivo.
OBJECTIVE: Leukocyte traffic from the blood to the joints is crucial in the pathogenesis of arthritis. A bifunctional endothelial cell-surface glycoprotein, AOC3 (amine oxidase, copper-containing 3; also known as vascular adhesion protein 1), has both adhesive and enzymatic properties. We undertook this study to determine the contribution of AOC3 and its oxidase activity to leukocyte trafficking into inflamed joints in vivo. METHODS: We used gene-modified animals, molecular modeling, an AOC3 enzyme inhibitor, oxidase assays, and arthritis models (adjuvant-induced arthritis [AIA] in rats and anti-type II collagen antibody-induced arthritis in mice) to dissect the importance of AOC3 in vivo. RESULTS: The AOC3 inhibitor fitted well with a covalent binding mode into the active site of the AOC3 crystal structure. It selectively blocked the oxidase activity of AOC3 in enzyme assays. Intraperitoneal and oral administration of the AOC3 inhibitor significantly ameliorated rat AIA. In anti-type II collagen antibody-induced arthritis in mice, the AOC3 inhibitor also improved the outcome of the joint inflammation. The acute semicarbazide-sensitive amine oxidase blockade by the inhibitor had even more pronounced effects than genetic deletion of AOC3. Enzymatic analyses showed that the inhibitor also blocked 2 other structurally very closely related AOCs, but not any of more than 100 other enzymes tested. CONCLUSION: These are the first data to demonstrate that the enzymatic activity of the atypical endothelial adhesion molecule AOC3, and possibly that of other closely related ecto-oxidases, is crucial for leukocyte exit from the vessels in inflamed joints in vivo.
Authors: Thomas Noonan; Susan Lukas; Gregory W Peet; Josephine Pelletier; Mark Panzenbeck; Adedayo Hanidu; Suzanne Mazurek; Ruby Wasti; Irina Rybina; Teresa Roma; Anthony Kronkaitis; Alycia Shoultz; Donald Souza; Huiping Jiang; Gerald Nabozny; Louise Kelly Modis Journal: Am J Clin Exp Immunol Date: 2013-06-15
Authors: Fatemeh Khodadust; Aiarpi Ezdoglian; Maarten M Steinz; Judy R van Beijnum; Gerben J C Zwezerijnen; Gerrit Jansen; Sander W Tas; Conny J van der Laken Journal: Int J Mol Sci Date: 2022-06-25 Impact factor: 6.208
Authors: Alexander I Aspinall; Stuart M Curbishley; Patricia F Lalor; Chris J Weston; Miroslava Blahova; Evaggelia Liaskou; Rebecca M Adams; Andrew P Holt; David H Adams Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Heli Elovaara; Teija Huusko; Mikael Maksimow; Kati Elima; Gennady G Yegutkin; Mikael Skurnik; Ulrich Dobrindt; Anja Siitonen; Michael J McPherson; Marko Salmi; Sirpa Jalkanen Journal: PLoS One Date: 2015-11-10 Impact factor: 3.240
Authors: Katherine Arndtz; Margaret Corrigan; Anna Rowe; Amanda Kirkham; Darren Barton; Richard P Fox; Laura Llewellyn; Amrita Athwal; Manpreet Wilkhu; Yung-Yi Chen; Chris Weston; Amisha Desai; David H Adams; Gideon M Hirschfield Journal: BMJ Open Date: 2017-07-03 Impact factor: 2.692